Phase III study of daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for amyloidosis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
- Indications Amyloidosis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 27 Jun 2017 Status changed from planning to not yet recruiting.
- 24 May 2017 New trial record
- 17 May 2017 According to a Gemmab media release, this study is currently planned to start between the second half of 2017 and the first quarter of 2018.